Glaxosmithkline Biologicals Sa

Smithkline Beecham Biologicals S.a.

Pfizer Ireland Pharmaceuticals

Carine Capiau

Jan Poolman

Dominique Boutriau

Ralph Leon Biemans

Pierre Duvivier

Philippe Denoel

Pierre Michel Desmons

Jean-Paul H Prieels

Dominique Lemoine

Dominique Ingrid Lemoine

Pierre Desmons

Craig Antony Joseph Laferriere

Marguerite Deschamps

Craig Antonyjoseph Laferriere

Martin Comberbach

Jean Petre

Piet Roelants

The present application discloses an immunogenic composition comprisingcapsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce acapsular polysaccharide conjugate, wherein the average size of eachpolysaccharide is above 50 kDa.

Immunogenic composition

The present application discloses an immunogenic composition comprising at least 2 differentcapsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated through a linker to a carrier protein(s), and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are directly conjugated to a carrier protein(s).

present application discloses an immunogenic composition comprisingcapsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce acapsular polysaccharide conjugate, wherein the average size of eachpolysaccharide is above 50 kDa.

The present application relates to an immunogenic composition comprising at least 2 conjugates ofcapsular saccharide and protein carrier, wherein said conjugates comprise at least 2 differentcapsular saccharides selected from the group consisting of MenA, MenC, MenY and MenW, wherein at least one capsular saccharide is conjugated to a protein carrier with a saccharide:protein ratio (w/w) between 1:2-1:5, and wherein at least one different capsular saccharide is conjugated to a protein carrier with a saccharide:protein ratio (w/w) between 5:1-1:1.99.

The present application discloses an immunogenic composition comprising at least 2 differentcapsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated to a protein carrier(s) wherein the saccharide:protein ratio (w/w) is between 1:2-1:5, and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are conjugated to a protein carrier(s) wherein the saccharide:protein ratio (w/w) is between 5:1-1:1.99.

The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 &#x3bc;g.

A multi-valent vaccine composition is described comprising a conjugate of the capsular polysaccharide ofb not adsorbed onto an aluminum adjuvant salt, and two or more further bacterial polysaccharides. A multi-valent vaccine composition is also described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, Hepatitis B surface antigen, a conjugate of the capsular polysaccharide ofb, and a conjugate of a capsular polysaccharide oftype A or C (or both). Furthermore, a multi-valent vaccine composition is described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, and a low dose of a conjugate of the capsular polysaccharide ofb.

Vaccine composition

The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from

Vaccine

The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example, saccharide conjugate(s), and a further antigen selected from the group consisting of whole celland hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 &#x3bc;g.

An immunogenic composition comprising a Hib saccharide conjugate and at least two further bacterial saccharide conjugates is provided, wherein the Hib conjugate is present in a lower saccharide dose than the mean saccharide dose of all the at least two further bacterial saccharide conjugates.

The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ug.

Extraction of cell-bound protein from bordetella

A process is provided for the purification of pertussis toxin (PT) and/or filamentous hemagglutinin antigen (FHA) from a B. pertussis fermentation broth or cell free culture supernatant containing at least one antigen, which comprises contacting the fermenation broth or cell free culture supernatant with a hydroxyapatite adsorbent for a sufficient time to adsorb the antigen(s) at a pH which both PT and FHA are adsorbed and eluting a mixture containing the adsorbed antigen(s) from the adsorbent with eluant at a pH which both PT and FHA are eluted. The PT and FHA may be further purified by two sequential chromatographic columns, one of which involves apolar-ligand chromatography.

Growing community of inventors

Rixensart, Belgium

Carine Capiau